![]() |
|||||||
|
Fusion Protein:FARP2-AFF3 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: FARP2-AFF3 | FusionPDB ID: 29388 | FusionGDB2.0 ID: 29388 | Hgene | Tgene | Gene symbol | FARP2 | AFF3 | Gene ID | 9855 | 3899 |
Gene name | FERM, ARH/RhoGEF and pleckstrin domain protein 2 | AF4/FMR2 family member 3 | |
Synonyms | FIR|FRG|PLEKHC3 | LAF4|MLLT2-like | |
Cytomap | 2q37.3 | 2q11.2 | |
Type of gene | protein-coding | protein-coding | |
Description | FERM, ARHGEF and pleckstrin domain-containing protein 2FERM domain including RhoGEFFERM, RhoGEF and pleckstrin domain protein 2FERM, RhoGEF and pleckstrin domain-containing protein 2FGD1-related Cdc42-GEFPH domain-containing family C member 3pleckst | AF4/FMR2 family member 3MLLT2-related proteinlymphoid nuclear protein 4lymphoid nuclear protein related to AF4protein LAF-4 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | O94887 Main function of 5'-partner protein: FUNCTION: Functions as guanine nucleotide exchange factor that activates RAC1. May have relatively low activity. Plays a role in the response to class 3 semaphorins and remodeling of the actin cytoskeleton. Plays a role in TNFSF11-mediated osteoclast differentiation, especially in podosome rearrangement and reorganization of the actin cytoskeleton. Regulates the activation of ITGB3, integrin signaling and cell adhesion (By similarity). {ECO:0000250}. | P51826 Main function of 5'-partner protein: FUNCTION: Putative transcription activator that may function in lymphoid development and oncogenesis. Binds, in vitro, to double-stranded DNA. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000264042, ENST00000373287, ENST00000545004, ENST00000479427, | ENST00000483600, ENST00000317233, ENST00000356421, ENST00000409236, ENST00000409579, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 5 X 4 X 4=80 | 14 X 19 X 6=1596 |
# samples | 5 | 16 | |
** MAII score | log2(5/80*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(16/1596*10)=-3.31831684133498 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: FARP2 [Title/Abstract] AND AFF3 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: FARP2 [Title/Abstract] AND AFF3 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | FARP2(242357524)-AFF3(100453986), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | FARP2-AFF3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FARP2-AFF3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FARP2-AFF3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. FARP2-AFF3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | FARP2 | GO:0016322 | neuron remodeling | 12351724 |
Hgene | FARP2 | GO:0016601 | Rac protein signal transduction | 12351724 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:242357524/chr2:100453986) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000264042 | FARP2 | chr2 | 242357524 | + | ENST00000409236 | AFF3 | chr2 | 100453986 | - | 9362 | 941 | 170 | 3748 | 1192 |
ENST00000264042 | FARP2 | chr2 | 242357524 | + | ENST00000356421 | AFF3 | chr2 | 100453986 | - | 7967 | 941 | 170 | 3748 | 1192 |
ENST00000264042 | FARP2 | chr2 | 242357524 | + | ENST00000317233 | AFF3 | chr2 | 100453986 | - | 7967 | 941 | 170 | 3748 | 1192 |
ENST00000264042 | FARP2 | chr2 | 242357524 | + | ENST00000409579 | AFF3 | chr2 | 100453986 | - | 4102 | 941 | 170 | 3748 | 1192 |
ENST00000545004 | FARP2 | chr2 | 242357524 | + | ENST00000409236 | AFF3 | chr2 | 100453986 | - | 9316 | 895 | 124 | 3702 | 1192 |
ENST00000545004 | FARP2 | chr2 | 242357524 | + | ENST00000356421 | AFF3 | chr2 | 100453986 | - | 7921 | 895 | 124 | 3702 | 1192 |
ENST00000545004 | FARP2 | chr2 | 242357524 | + | ENST00000317233 | AFF3 | chr2 | 100453986 | - | 7921 | 895 | 124 | 3702 | 1192 |
ENST00000545004 | FARP2 | chr2 | 242357524 | + | ENST00000409579 | AFF3 | chr2 | 100453986 | - | 4056 | 895 | 124 | 3702 | 1192 |
ENST00000373287 | FARP2 | chr2 | 242357524 | + | ENST00000409236 | AFF3 | chr2 | 100453986 | - | 9308 | 887 | 116 | 3694 | 1192 |
ENST00000373287 | FARP2 | chr2 | 242357524 | + | ENST00000356421 | AFF3 | chr2 | 100453986 | - | 7913 | 887 | 116 | 3694 | 1192 |
ENST00000373287 | FARP2 | chr2 | 242357524 | + | ENST00000317233 | AFF3 | chr2 | 100453986 | - | 7913 | 887 | 116 | 3694 | 1192 |
ENST00000373287 | FARP2 | chr2 | 242357524 | + | ENST00000409579 | AFF3 | chr2 | 100453986 | - | 4048 | 887 | 116 | 3694 | 1192 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000264042 | ENST00000409236 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000388796 | 0.9996112 |
ENST00000264042 | ENST00000356421 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000511412 | 0.9994886 |
ENST00000264042 | ENST00000317233 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000511412 | 0.9994886 |
ENST00000264042 | ENST00000409579 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.004527342 | 0.9954726 |
ENST00000545004 | ENST00000409236 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000369877 | 0.9996301 |
ENST00000545004 | ENST00000356421 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000487231 | 0.9995128 |
ENST00000545004 | ENST00000317233 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000487231 | 0.9995128 |
ENST00000545004 | ENST00000409579 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.004471813 | 0.99552816 |
ENST00000373287 | ENST00000409236 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000359553 | 0.99964046 |
ENST00000373287 | ENST00000356421 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000473309 | 0.99952674 |
ENST00000373287 | ENST00000317233 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.000473309 | 0.99952674 |
ENST00000373287 | ENST00000409579 | FARP2 | chr2 | 242357524 | + | AFF3 | chr2 | 100453986 | - | 0.004274751 | 0.9957253 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for FARP2-AFF3 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
FARP2 | chr2 | 242357524 | AFF3 | chr2 | 100453986 | 887 | 253 | GTKIQLAVSHMGVLVFQESRSGETNS |
FARP2 | chr2 | 242357524 | AFF3 | chr2 | 100453986 | 895 | 253 | GTKIQLAVSHMGVLVFQESRSGETNS |
FARP2 | chr2 | 242357524 | AFF3 | chr2 | 100453986 | 941 | 253 | GTKIQLAVSHMGVLVFQESRSGETNS |
Top |
Potential FusionNeoAntigen Information of FARP2-AFF3 in HLA I |
![]() |
FARP2-AFF3_242357524_100453986.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:24 | SHMGVLVF | 0.9994 | 0.5066 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:01 | SHMGVLVF | 0.9986 | 0.7682 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:10 | SHMGVLVF | 0.9985 | 0.6852 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B38:02 | SHMGVLVF | 0.9979 | 0.8353 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B38:01 | SHMGVLVF | 0.9977 | 0.8291 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B14:01 | SHMGVLVF | 0.9932 | 0.7247 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B14:02 | SHMGVLVF | 0.9932 | 0.7247 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:37 | SHMGVLVF | 0.9917 | 0.7447 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:18 | SHMGVLVF | 0.9913 | 0.7402 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B57:01 | VSHMGVLVF | 0.9983 | 0.9051 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:25 | VSHMGVLVF | 0.9979 | 0.9313 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:17 | VSHMGVLVF | 0.9976 | 0.8969 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B58:02 | VSHMGVLVF | 0.9965 | 0.7477 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B58:01 | VSHMGVLVF | 0.9958 | 0.8219 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:16 | VSHMGVLVF | 0.9957 | 0.7995 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:01 | VSHMGVLVF | 0.9952 | 0.8623 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:03 | VSHMGVLVF | 0.9923 | 0.7838 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B57:03 | VSHMGVLVF | 0.9921 | 0.8039 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-A32:13 | VSHMGVLVF | 0.7524 | 0.8278 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:09 | SHMGVLVF | 0.9992 | 0.6459 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:12 | SHMGVLVF | 0.9986 | 0.7737 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:05 | SHMGVLVF | 0.9977 | 0.7563 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B14:03 | SHMGVLVF | 0.8162 | 0.7513 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:19 | LAVSHMGVL | 0.9991 | 0.9947 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:08 | LAVSHMGVL | 0.9989 | 0.9403 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:07 | LAVSHMGVL | 0.9985 | 0.9897 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:07 | VSHMGVLVF | 0.9969 | 0.6995 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:08 | VSHMGVLVF | 0.9943 | 0.9444 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:19 | VSHMGVLVF | 0.9919 | 0.9192 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C15:04 | VSHMGVLVF | 0.9915 | 0.9236 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:12 | LAVSHMGVL | 0.9859 | 0.974 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C06:03 | LAVSHMGVL | 0.9824 | 0.996 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:04 | LAVSHMGVL | 0.9819 | 0.9954 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:05 | VSHMGVLVF | 0.981 | 0.83 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:07 | VSHMGVLVF | 0.9745 | 0.9863 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C08:13 | LAVSHMGVL | 0.9575 | 0.9925 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C08:04 | LAVSHMGVL | 0.9575 | 0.9925 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:12 | VSHMGVLVF | 0.9575 | 0.8741 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:14 | VSHMGVLVF | 0.8578 | 0.9056 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C06:03 | VSHMGVLVF | 0.8412 | 0.9806 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C02:06 | LAVSHMGVL | 0.8304 | 0.9743 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:04 | VSHMGVLVF | 0.8265 | 0.9802 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:14 | LAVSHMGVL | 0.8093 | 0.9844 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:31 | SHMGVLVF | 0.9985 | 0.7703 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B38:05 | SHMGVLVF | 0.9977 | 0.8291 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:09 | SHMGVLVF | 0.9938 | 0.7012 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B39:11 | SHMGVLVF | 0.9405 | 0.7535 | 8 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:03 | LAVSHMGVL | 0.9992 | 0.9946 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:04 | LAVSHMGVL | 0.9992 | 0.9946 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B57:04 | VSHMGVLVF | 0.9989 | 0.6773 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:02 | VSHMGVLVF | 0.9987 | 0.9729 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:05 | LAVSHMGVL | 0.9985 | 0.9434 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:17 | LAVSHMGVL | 0.9985 | 0.9786 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B57:10 | VSHMGVLVF | 0.9983 | 0.9051 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:39 | VSHMGVLVF | 0.9975 | 0.835 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B58:06 | VSHMGVLVF | 0.9973 | 0.6726 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:135 | VSHMGVLVF | 0.9958 | 0.853 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:27 | VSHMGVLVF | 0.9957 | 0.8655 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:04 | VSHMGVLVF | 0.9956 | 0.9859 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:03 | VSHMGVLVF | 0.9956 | 0.9859 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:24 | VSHMGVLVF | 0.9953 | 0.7743 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:125 | VSHMGVLVF | 0.9952 | 0.8623 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:33 | VSHMGVLVF | 0.9952 | 0.8623 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:34 | VSHMGVLVF | 0.9952 | 0.8623 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:35 | VSHMGVLVF | 0.9945 | 0.7582 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:50 | VSHMGVLVF | 0.9919 | 0.9051 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C16:04 | VSHMGVLVF | 0.9916 | 0.9618 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C15:09 | VSHMGVLVF | 0.9915 | 0.9236 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:05 | VSHMGVLVF | 0.9913 | 0.8003 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:17 | VSHMGVLVF | 0.9912 | 0.8665 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C16:04 | LAVSHMGVL | 0.9905 | 0.9871 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:02 | LAVSHMGVL | 0.9904 | 0.9794 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:03 | LAVSHMGVL | 0.9902 | 0.9881 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:02 | LAVSHMGVL | 0.9895 | 0.9768 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B57:02 | VSHMGVLVF | 0.9888 | 0.758 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B15:20 | VSHMGVLVF | 0.9827 | 0.9081 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C03:06 | LAVSHMGVL | 0.9824 | 0.9946 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-B35:28 | VSHMGVLVF | 0.9774 | 0.9192 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:02 | VSHMGVLVF | 0.9717 | 0.9703 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C12:03 | VSHMGVLVF | 0.9658 | 0.9559 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C16:01 | VSHMGVLVF | 0.8459 | 0.9627 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C16:01 | LAVSHMGVL | 0.8439 | 0.987 | 5 | 14 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C16:02 | VSHMGVLVF | 0.5309 | 0.9821 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C02:10 | VSHMGVLVF | 0.3018 | 0.9542 | 7 | 16 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | HLA-C02:02 | VSHMGVLVF | 0.3018 | 0.9542 | 7 | 16 |
Top |
Potential FusionNeoAntigen Information of FARP2-AFF3 in HLA II |
![]() |
FARP2-AFF3_242357524_100453986.msa |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-0437 | MGVLVFQESRSGETN | 10 | 25 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-0437 | HMGVLVFQESRSGET | 9 | 24 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-0444 | MGVLVFQESRSGETN | 10 | 25 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-0473 | MGVLVFQESRSGETN | 10 | 25 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-1503 | HMGVLVFQESRSGET | 9 | 24 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-1503 | SHMGVLVFQESRSGE | 8 | 23 |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 | DRB1-1523 | HMGVLVFQESRSGET | 9 | 24 |
Top |
Fusion breakpoint peptide structures of FARP2-AFF3 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
711 | AVSHMGVLVFQESR | FARP2 | AFF3 | chr2 | 242357524 | chr2 | 100453986 | 941 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FARP2-AFF3 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 711 | AVSHMGVLVFQESR | -7.9962 | -8.1096 |
HLA-B14:02 | 3BVN | 711 | AVSHMGVLVFQESR | -5.70842 | -6.74372 |
HLA-B52:01 | 3W39 | 711 | AVSHMGVLVFQESR | -6.83737 | -6.95077 |
HLA-B52:01 | 3W39 | 711 | AVSHMGVLVFQESR | -4.4836 | -5.5189 |
HLA-A11:01 | 4UQ2 | 711 | AVSHMGVLVFQESR | -10.0067 | -10.1201 |
HLA-A11:01 | 4UQ2 | 711 | AVSHMGVLVFQESR | -9.03915 | -10.0745 |
HLA-A24:02 | 5HGA | 711 | AVSHMGVLVFQESR | -6.56204 | -6.67544 |
HLA-A24:02 | 5HGA | 711 | AVSHMGVLVFQESR | -5.42271 | -6.45801 |
HLA-B44:05 | 3DX8 | 711 | AVSHMGVLVFQESR | -7.85648 | -8.89178 |
HLA-B44:05 | 3DX8 | 711 | AVSHMGVLVFQESR | -5.3978 | -5.5112 |
HLA-A02:01 | 6TDR | 711 | AVSHMGVLVFQESR | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of FARP2-AFF3 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 5 | 14 | LAVSHMGVL | CACATGGGTGTACTCGTGTTCCAGGAG |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 7 | 16 | VSHMGVLVF | GGTGTACTCGTGTTCCAGGAGAGTAGA |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 8 | 16 | SHMGVLVF | GTACTCGTGTTCCAGGAGAGTAGA |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 10 | 25 | MGVLVFQESRSGETN | GTGTTCCAGGAGAGTAGATCTGGAGAAACCAACAGCTGTGTTGAA |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 8 | 23 | SHMGVLVFQESRSGE | GTACTCGTGTTCCAGGAGAGTAGATCTGGAGAAACCAACAGCTGT |
FARP2-AFF3 | chr2 | 242357524 | chr2 | 100453986 | 9 | 24 | HMGVLVFQESRSGET | CTCGTGTTCCAGGAGAGTAGATCTGGAGAAACCAACAGCTGTGTT |
Top |
Information of the samples that have these potential fusion neoantigens of FARP2-AFF3 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
OV | FARP2-AFF3 | chr2 | 242357524 | ENST00000264042 | chr2 | 100453986 | ENST00000317233 | TCGA-36-1571 |
Top |
Potential target of CAR-T therapy development for FARP2-AFF3 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to FARP2-AFF3 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to FARP2-AFF3 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | AFF3 | C0003873 | Rheumatoid Arthritis | 2 | CTD_human |
Tgene | AFF3 | C0013146 | Drug abuse | 1 | CTD_human |
Tgene | AFF3 | C0013170 | Drug habituation | 1 | CTD_human |
Tgene | AFF3 | C0013222 | Drug Use Disorders | 1 | CTD_human |
Tgene | AFF3 | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
Tgene | AFF3 | C0036572 | Seizures | 1 | GENOMICS_ENGLAND |
Tgene | AFF3 | C0038580 | Substance Dependence | 1 | CTD_human |
Tgene | AFF3 | C0038586 | Substance Use Disorders | 1 | CTD_human |
Tgene | AFF3 | C0236969 | Substance-Related Disorders | 1 | CTD_human |
Tgene | AFF3 | C0740858 | Substance abuse problem | 1 | CTD_human |
Tgene | AFF3 | C1510472 | Drug Dependence | 1 | CTD_human |
Tgene | AFF3 | C3714756 | Intellectual Disability | 1 | GENOMICS_ENGLAND |
Tgene | AFF3 | C4316881 | Prescription Drug Abuse | 1 | CTD_human |